Cedara collaborates with UCLA on cardiology systemCedara Software is working with researchers from the University of California, Los Angeles, to develop and implement a new medical imaging workstation for cardiology.The system will be designed
Cedara Software is working with researchers from the University of California, Los Angeles, to develop and implement a new medical imaging workstation for cardiology.
The system will be designed to provide a single source for capture, review, and analysis of multimodality cardiology images, including angiography, cardiac ultrasound, and MRI. This should enhance clinical decision-making and increase physician efficiency by facilitating data gathering, according to Toronto-based Cedara. The imaging software company, which demonstrated a prototype of this technology at the American Heart Association meeting last November, says no currently available technology allows cardiology images from different modalities to be reviewed on a single platform.
The market for cardiology imaging products is expected to reach $2.25 billion by 2003, according to industry analysts Frost & Sullivan.
© 2000 Miller Freeman, Inc., a United News & Media company.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.